Sanofi has announced that it will lower the list price of its insulin drug, Lantus, by 78 percent and will set a $35 cap on out-of-pocket costs for all patients.
The price change and cap will go into effect starting January 1, 2024. They follow a series of moves made last year to lower the price of diabetes medicine, including the launch of an unbranded version of Lantus and a $35 cap for uninsured patients.
Yet, Olivier Bogillot, head of U.S. general medicines at Sanofi, said "the health system was unable to take advantage of it due to its inherent structural challenges."
“Sanofi believes that no one should struggle to pay for their insulin and we are proud of our continued actions to improve access and affordability for millions of patients for many years," he said. "Our decision to cut the list price of our lead insulin needs to be coupled with broader change to the overall system to actually drive savings for patients at the pharmacy counter.”
Sanofi will also cut the price of short-acting Apidra by 70 percent.
Founder & CEO at Align Business Advisory, Dena Jalbert, joins Cheddar to discuss the future of the M&A space and which sectors to watch out for. Watch!
Working five days a week has long been the corporate cultural norm. But some companies are exploring the option of letting employees work four days a week.
After a two-year-long high, interest rates are coming back to earth. So what happens next? Plus: Boeing's woes, UAW may strike, and of course Elon's World.
PLUS: American Eagle marks 30 NYSE years with a record stock high. CMO Craig Brommers discusses Gen-Z trends and collabs with Coco Gauff and Trevor Lawrence.
